Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04803435
Other study ID # 36793220300000071
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 20, 2022
Est. completion date December 2022

Study information

Verified date March 2021
Source Hospital Israelita Albert Einstein
Contact Tarso AD Accorsi, MD, PhD
Phone +55 11 2151 2773
Email tarsoa@einstein.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute gastroenterocolitis (GECA) in healthy adults is a frequent cause of looking for medical care in emergency care units and most cases are aimed at etiology viral infection or food toxin, being generally self-limited with good prognosis and only need for treatment with behavioral measures and use of medications for relief symptomatic. Anamnesis is the main resource for the diagnosis and stratification of GECA severity and is infrequent alterations of physical examination and complementary examinations without association with symptoms of alert. Telemedicine has become a resource that allows easier and faster access to medical evaluation, with low cost and rational use of resources. Virtual emergency care is part of Hospital Israelita Albert Einstein (HIAE) institutional routine and there is a large number of consultations whose final diagnosis was GECA. It is not known whether the accuracy of diagnosis of GECA by telemedicine is not inferior to the diagnosis by face-to-face evaluation, considered the Golden pattern. The aim of the study is compare the diagnostic accuracy of GECA by telemedicine with that of face-to-face care. It is a prospective randomized study with a population of adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious). Patients whose screening will be excluded of nursing directed for immediate evaluation in the emergency room and patients with dysfunctions organisms or immunosuppression. Patients who accept and sign the informed consent form will be randomized into 2 groups: A) immediate face-to-face evaluation; B) evaluation initially by telemedicine and sequentially at face-to-face evaluation. In both cases, the ICD diagnostics will be compiled and grouped according to clinical significance and will be the primary outcome of the study. Service time, exams requested, guidelines, prescription and destination will also be analyzed. Patients and doctors who undergoing group B assessment will be blinded to the telemedicine assessment data.


Description:

The face-to-face assessment will be carried out by the local UPA medical and assistance team and the assessment by telemedicine by the fixed medical team of the HIAE service responsible for urgency / emergency. Both in face-to-face evaluation, as well as telemedicine, clinical data, final diagnosis, destination, total time of care, guidance and prescription will be computed. In the face-to-face evaluation, complementary exams and medications received in situ were computed. Final diagnoses will receive nomenclature according to the International Statistical Classification of Diseases and Problems Health-Related - ICD 10 (institutional medical record requirement - Cerner) and will be grouped according to equivalence of syndromic diagnosis. The diagnosis of the face-to-face assessment is made according to protocols based on extensive medical literature and approved by the institutional clinical staff, being representative of current medical practice and will be considered the gold standard diagnosis. Patients evaluated by telemedicine will be blinded to the diagnosis, recommended destination, guidelines and prescription performed by the medical team. UPA doctors will be blind to the doctor's assessment telemedicine and telemedicine doctors will not have access to the data obtained in the screening.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age> 18 years - Symptoms present less than 7 days. - Without the use of antibiotics in last 30 days prior to the onset of symptoms. - No trips abroad in the last 15 days prior to the onset of symptoms. - Presence of more than three episodes of watery diarrhea in the last 24 hours with or without symptoms related to the infection (fever 38oC, chills, sweating, myalgia, vomiting) that motivated / were looking for the Emergency Care Unit - Signature of informed consent form Exclusion Criteria: - Return to the Emergency Care Unit due to maintenance or aggravation of the complaint - Age> 65 years - Diagnosis of chronic gastrointestinal diseases, gastritis with or without gastroesophageal reflux disease, previous diverticulitis, previous abdominal surgery, chronic colitis, inflammatory bowel diseases, food intolerances (gluten, lactose) - Previous diagnosis of congestive heart failure, HIV / AIDS, active cancer, type I diabetes mellitus, use of any immunosuppressant - Diarrhea chronic - Patient with emergency room criteria by the nursing evaluation of the triage.

Study Design


Intervention

Other:
Telemedicine Consultation
Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.
Face-to-face Consultation
Direct face-to-face evaluation (without telemedicine consultation before).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hospital Israelita Albert Einstein

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy of telemedicine diagnosis of adult patients with symptoms compatible with acute gastrointestinal infection The patient will be evaluated by telemedicine and / or face-to-face consultation and at the end will receive the diagnosis, which will be assigned the ICD code. At the end, these ICDs will be grouped by the same clinical significance and will be compared between the two consultation methods (telemedicine versus face-to-face consultation). through study completion, an average of 1 year
Secondary Time of medical care Comparison of time (minutes) of medical care between telemedicine and face-to-face consultation. through study completion, an average of 1 year
Secondary Rate of indication for complementary exams Comparison of rate (porcentage) of indication for complementary exams between telemedicine and face-to-face consultation. through study completion, an average of 1 year
Secondary Types of requested exams Comparison of types of requested exams (porcentage) between telemedicine and face-to-face consultation. through study completion, an average of 1 year
Secondary Guidelines follow-up Comparison of guidelines follow-up (porcentage) between telemedicine and face-to-face consultation. through study completion, an average of 1 year
Secondary Medical prescription Comparison of medical prescription after completion of the service between telemedicine and face-to-face consultation. through study completion, an average of 1 year
Secondary Proposed destination after completion of the service Comparison of proposed destination (percentage of discharge or hospitalization) after completion of the service between telemedicine and face-to-face consultation. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05484102 - Preventive Effect of Cow's Milk Fermented With Lactobacillus Paracasei CBA L74 on Common Infectious Diseases in Children N/A
Enrolling by invitation NCT03299283 - Specimen Collection and Transport Workflow Evaluations for CLIA-waived Molecular Testing
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Active, not recruiting NCT04258059 - Wells and Enteric Disease Transmission Trial (WET - Trial) N/A
Enrolling by invitation NCT04501380 - Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) Phase 2
Recruiting NCT04826991 - Wells and Enteric Disease Transmission N/A
Completed NCT03454009 - Kent State University / Price Chopper Employee Wellness Study N/A
Enrolling by invitation NCT05051358 - Therapeutic Endoscopic Ultrasound for Gastrointestinal Disorders: A Multicenter Registry Study
Enrolling by invitation NCT05977868 - Comparing Oral Versus Parenteral Antimicrobial Therapy Phase 4
Recruiting NCT03342547 - Identification of Host Factors of Norovirus Infections in Mini-Gut Model N/A